Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v2.4.0.6
Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2011
Dec. 31, 2010
Assets    
Cash $ 5,406 $ 3,180
Receivables 3,720 1,225
Prepaid expenses and other current assets 836 294
Total current assets 9,962 4,699
Property and equipment, net 255 53
Total Assets 10,217 4,752
Liabilities and Stockholders' Deficit    
Accounts payable 4,789 2,457
Accrued clinical trials expenses 161 705
Other accrued liabilities 173 373
Current portion of long-term debt   1,870
Total current liabilities 5,123 5,405
Warrant liability 3,611  
Royalty liability 9,309  
Long-term debt, net of discount 12,253 5,400
Total Liabilities 30,296 10,805
Commitments and contingencies      
Stockholders' deficit:    
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued and outstanding      
Common stock, at amounts paid in, $0.001 par value per share; 125,000,000 shares authorized, 59,386,542 and 59,247,742 shares issued and outstanding at December 31, 2011 and 2010, respectively 256,436 256,436
Additional paid-in capital 18,433 17,256
Accumulated deficit (294,948) (279,745)
Total stockholders' deficit (20,079) (6,053)
Total Liabilities and Stockholders' Deficit $ 10,217 $ 4,752